Population-based study of blood biomarkers in prediction of subacute recurrent stroke

Stroke

Volumn 45, Issue 10, 2014, Pages 2912-2917

  Segal, Helen C ^a   Burgess, Annette I ^a   Poole, Debbie L ^a   Mehta, Ziyah ^a   Silver, Louise E ^a   Rothwell, Peter M ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; C REACTIVE PROTEIN; D DIMER; ENOLASE; FATTY ACID BINDING PROTEIN; FIBRINOGEN; HEART TYPE FATTY ACID BINDING PROTEIN; INTERLEUKIN 6; NEURONE SPECIFIC ENOLASE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PADGEM PROTEIN; THROMBOMODULIN; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

AGE; AGED; ARTICLE; ATHEROGENESIS; BLOOD ANALYSIS; BLOOD SAMPLING; BRAIN ISCHEMIA; CELL DAMAGE; CEREBROVASCULAR ACCIDENT; DIABETES MELLITUS; FEMALE; HEART MUSCLE CELL; HUMAN; HYPERTENSION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; NERVE CELL LESION; POPULATION RESEARCH; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECURRENCE RISK; RECURRENT DISEASE; SEX; SMOKING; SUBACUTE RECURRENT STROKE; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; BLOOD; COMPLICATION; IMMUNOASSAY; MIDDLE AGED; STROKE;

AGED; BIOMARKERS; FEMALE; HUMANS; IMMUNOASSAY; INFLAMMATION; MALE; MIDDLE AGED; RECURRENCE; STROKE;

EID: 84930160799     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.114.005592     Document Type: Article

References (37)

1. Giles MF, Rothwell PM. Systematic review and pooled analysis of published and unpublished validations of the ABCD and ABCD2 transient ischemic attack risk scores. Stroke. 2010;41:667-673.
2. Giles MF, Albers GW, Amarenco P, Arsava MM, Asimos A, Ay H, et al. Addition of brain infarction to the ABCD2 Score (ABCD2I): A collaborative analysis of unpublished data on 4574 patients. Stroke. 2010;41:1907-1913.
3. Merwick A, Albers GW, Amarenco P, Arsava EM, Ay H, Calvet D, et al. Addition of brain and carotid imaging to the ABCD2 score to identify patients at early risk of stroke after transient ischaemic attack: A multicentre observational study. Lancet Neurol. 2010;9:1060-1069.
4. Zakai NA, Katz R, Jenny NS, Psaty BM, Reiner AP, Schwartz SM, et al. Inflammation and hemostasis biomarkers and cardiovascular risk in the elderly: The Cardiovascular Health Study. J Thromb Haemost. 2007;5:1128-1135.
5. Blankenberg S, Zeller T, Saarela O, Havulinna AS, Kee F, Tunstall-Pedoe H, et al; MORGAM Project. Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: The MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project. Circulation. 2010;121:2388-2397.
6. Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, White IR, Gao P, et al. C-reactive protein, fibrinogen and cardiovascular disease prediction. Emerging Risk Factors Collaboration. N Eng J Med. 2012;367:1310-1320.
7. Whiteley W, Wardlaw J, Dennis M, Lowe G, Rumley A, Sattar N, et al. The use of blood biomarkers to predict poor outcome after acute transient ischemic attack or ischemic stroke. Stroke. 2012;43:86-91.
8. Maas MB, Furie KL. Molecular biomarkers in stroke diagnosis and prognosis. Biomark Med. 2009;3:363-383.
9. Saenger AK, Christenson RH. Stroke biomarkers: progress and challenges for diagnosis, prognosis, differentiation, and treatment. Clin Chem. 2010;56:21-33.
10. Hasan N, McColgan P, Bentley P, Edwards RJ, Sharma P. Towards the identification of blood biomarkers for acute stroke in humans: A comprehensive systematic review. Br J Clin Pharmacol. 2012;74:230-240.
11. Welsh P, Lowe GD, Chalmers J, Campbell DJ, Rumley A, Neal BC, et al. Associations of proinflammatory cytokines with the risk of recurrent stroke. Stroke. 2008;39:2226-2230.
12. Elkind MSV, Luna JM, McClure LA, Zhang Y, Coffey CS, Roldan A, et al. C-Reactive protein as a prognostic markers after lacunar stroke. Stroke. 2014;45:1-10.
13. Whiteley W, Chong WL, Sengupta A, Sandercock P. Blood markers for the prognosis of ischemic stroke: A systematic review. Stroke. 2009;40:e380-e389.
14. Selvarajah JR, Smith CJ, Hulme S, Georgiou R, Sherrington C, Staniland J, et al. Does inflammation predispose to recurrent vascular events after recent transient ischaemic attack and minor stroke? The North West of England transient ischaemic attack and minor stroke (NORTHSTAR) study. Int J Stroke. 2011;6:187-194.
15. Corso G, Bottacchi E, Brusa A, Lia C, Cordera S, Giardini G, et al. Blood C-reactive protein concentration with ABCD2 is a better prognostic tool than ABCD2 alone. Cerebrovasc Dis. 2011;32:97-105.
16. Cucchiara BL, Messe SR, Sansing L, MacKenzie L, Taylor RA, Pacelli J, et al. Lipoprotein-associated phospholipase A2 and C-reactive protein for risk-stratification of patients with TIA. Stroke. 2009;40:2332-2336.
17. Park SY, Kim J, Kim OJ, Kim JK, Song J, Shin DA, et al. Predictive value of circulating interleukin-6 and heart-type fatty acid binding protein for three months clinical outcome in acute cerebral infarction: multiple blood markers profiling study. Crit Care. 2013;17:R45.
18. Sofi F, Cesari F, Abbate R, Gensini GF, Broze G Jr, Fedi S. A metaanalysis of potential risks of low levels of protein Z for diseases related to vascular thrombosis. Thromb Haemost. 2010;103:749-756.
19. Fiskesund R, Stegmayr B, Vikstrom M, Weinehall L, de Faire U, Frostegard J. Low levels of antibodies against phosphorylcholine predict development of stroke in a population-based study from northern Sweden. Stroke. 2010;41:607-612.
20. Rothwell PM, Coull AJ, Giles MF, Howard SC, Silver LE, Bull LM, et al; Oxford Vascular Study. Change in stroke incidence, mortality, casefatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). Lancet. 2004;363:1925-1933.
21. Coull AJ, Silver LE, Bull LM, Giles MF, Rothwell PM; Oxford Vascular (OXVASC) Study. Direct assessment of completeness of ascertainment in a stroke incidence study. Stroke. 2004;35:2041-2045.
22. Rothwell PM, Coull AJ, Silver LE, Fairhead JF, Giles MF, Lovelock CE, et al; Oxford Vascular Study. Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet. 2005;366:1773-1783.
23. Brott T, Adams HP Jr, Olinger CP, Marler JR, Barsan WG, Biller J, et al. Measurements of acute cerebral infarction: A clinical examination scale. Stroke. 1989;20:864-870.
24. Rothwell PM, Giles MF, Chandratheva A, Marquardt L, Geraghty O, Redgrave JN, et al; Early use of Existing Preventive Strategies for Stroke (EXPRESS) study. Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): A prospective population-based sequential comparison. Lancet. 2007;370:1432-1442.
25. Di Napoli M, Schwaninger M, Cappelli R, Ceccarelli E, Di Gianfilippo G, Donati C, et al. Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: A statement for health care professionals from the CRP Pooling Project members. Stroke. 2005;36:1316-1329.
26. Whiteley W, Jackson C, Lewis S, Lowe G, Rumley A, Sandercock P, et al. Inflammatory markers and poor outcome after stroke: A prospective cohort study and systematic review of interleukin-6. Plos Medicine. 2009;6:1-12.
27. Welsh P, Barber M, Langhorne P, Rumley A, Lowe GD, Stott DJ. Associations of inflammatory and haemostatic biomarkers with poor outcome in acute ischaemic stroke. Cerebrovasc Dis. 2009;27:247-253.
28. Tuttolomondo A, Di Sciacca R, Di Raimondo D, Serio A, D'Aguanno G, La Placa S, et al. Plasma levels of inflammatory and thrombotic/fibrinolytic markers in acute ischemic strokes: relationship with TOAST subtype, outcome and infarct site. J Neuroimmunol. 2009;215:84-89.
29. Wiseman S, Marlborough F, Doubal F, Webb DJ, Wardlaw J. Blood markers of coagulation, fibrinolysis, endothelial dysfunction and inflammation in lacunar stroke versus non-lacunar stroke and non-stroke: systematic review and meta-analysis. Cerebrovasc Dis. 2014;37:64-75.
30. Carter AM, Anagnostopoulou K, Mansfield MW, Grant PJ. Soluble P-selectin levels, P-selectin polymorphisms and cardiovascular disease. J Thromb Haemost. 2003;1:1718-1723.
31. Kornej J, Apostolakis S, Bollmann A, Lip GY. The emerging role of biomarkers in atrial fibrillation. Can J Cardiol. 2013;29:1181-1193.
32. Grönlund H, Hallmans G, Jansson JH, Boman K, Wikström M, de Faire U, et al. Low levels of IgM antibodies against phosphorylcholine predict development of acute myocardial infarction in a population-based cohort from northern Sweden. Eur J Cardiovasc Prev Rehabil. 2009;16:382-386.
33. Sjöberg BG, Su J, Dahlbom I, Grönlund H, Wikström M, Hedblad B, et al. Low levels of IgM antibodies against phosphorylcholine-A potential risk marker for ischemic stroke in men. Atherosclerosis. 2009;203:528-532.
34. Danesh J, Lewington S, Thompson SG. Plasma fibrinogen and the risk of major cardiovascular diseases and non-vascular mortality: An individual participant meta-analysis. JAMA. 2005;294:1799-1809.
35. Rothwell PM, Howard SC, Power DA, Gutnikov SA, Algra A, van Gijn J, et al. Fibrinogen concentration and risk of ischemic stroke and acute coronary events in 5113 patients with transient ischemic attack and minor ischemic stroke. Stroke. 2004;35:2300-2305.
36. Barber M, Langhorne P, Rumley A, Lowe GD, Stott DJ. Hemostatic function and progressing ischemic stroke: D-dimer predicts early clinical progression. Stroke. 2004;35:1421-1430.
37. Hanson E, Jood K, Karlsson S, Nilsson S, Blomstrand C, Jern C. Plasma levels of von Willebrand factor in the etiologic subtypes of ischemic stroke. J Thromb Haemost. 2011;9:275-281.